Resolution of a warfarin and dabigatran-resistant left atrial appendage thrombus with apixaban

The majority of embolisms associated with atrial fibrillation (AF) are from the left atrial appendage (LAA). To treat the existing thrombus, warfarin and novel anticoagulants have been used. However, there has been no clinical information regarding the difference of the effects of congealing the fib...

Descripción completa

Detalles Bibliográficos
Autores principales: Miwa, Yosuke, Minamishima, Toshinori, Sato, Toshiaki, Sakata, Konomi, Yoshino, Hideaki, Soejima, Kyoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Rapid Firing
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913128/
https://www.ncbi.nlm.nih.gov/pubmed/27354873
http://dx.doi.org/10.1016/j.joa.2016.01.009
Descripción
Sumario:The majority of embolisms associated with atrial fibrillation (AF) are from the left atrial appendage (LAA). To treat the existing thrombus, warfarin and novel anticoagulants have been used. However, there has been no clinical information regarding the difference of the effects of congealing the fibrinogenolysis system among these oral anticoagulants. Here, we report a case of persistent AF, in whom apixaban, factor Xa inhibitor resolved an LAA clot refractory to warfarin and direct thrombin inhibition. Factor Xa inhibitor, apixaban, could resolve the left appendage thrombosis refractory to warfarin and dabigatran.

Ejemplares similares